Skip to Main Content
DownloadHi-Res Photo

Asher Marks, MD

Assistant Professor of Pediatrics (Hematology / Oncology); Director, Pediatric Neuro-Oncology

Contact Information

Asher Marks, MD

Mailing Address

  • Pediatric Hematology & Oncology

    PO Box 208064

    New Haven, CT 06520-8064

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Marks' research interests include the treatment of pediatric brain tumors and unique needs of adolescent oncology patients, as well as the incorporation of digital technologies into the treatment of these patient populations.

Specialized Terms: Adolescent Oncology; Pediatric Neuro-Oncology; Long Term Effects

Coauthors

Research Interests

Brain Neoplasms; Hematology; Medical Oncology; Neoplasms; Pediatrics; Virtual Reality; Digital Divide

Selected Publications

  • Index of suspicion.Maniscalco J, Dryer AL, Marks A, Yunghans M, Pierson SB, Sgarlat CM, Sveen AR, Blanch LE. Index of suspicion. Pediatrics In Review / American Academy Of Pediatrics 2008, 29: 321-8. PMID: 18765471, DOI: 10.1542/pir.29-9-321.
  • A review of secondary central nervous system tumors after treatment of a primary pediatric malignancy.Marks AM, Packer RJ. A review of secondary central nervous system tumors after treatment of a primary pediatric malignancy. Seminars In Pediatric Neurology 2012, 19: 43-8. PMID: 22641075, DOI: 10.1016/j.spen.2012.02.015.
  • Hemoglobin Shady Grove: a novel fetal methemoglobin variant.Marks A, Luo HY, Chui DH, Greenberg J. Hemoglobin Shady Grove: a novel fetal methemoglobin variant. Pediatric Blood & Cancer 2013, 60: E55-6. PMID: 23460588, DOI: 10.1002/pbc.24503.
  • Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.Hong CS, Vasquez JC, Kundishora AJ, Elsamadicy AA, Beckta JM, Sule A, Marks AM, Leelatian N, Huttner A, Bindra RS, DiLuna ML, Kahle KT, Erson-Omay EZ. Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma. NPJ Genomic Medicine 2020, 5: 23. PMID: 32528726, PMCID: PMC7264170, DOI: 10.1038/s41525-020-0130-7.
  • Genomic alterations underlying spinal metastases in pediatric H3K27M-mutant pineal parenchymal tumor of intermediate differentiation: case report.Fomchenko EI, Erson-Omay EZ, Kundishora AJ, Hong CS, Daniel AA, Allocco A, Duy PQ, Darbinyan A, Marks AM, DiLuna ML, Kahle KT, Huttner A. Genomic alterations underlying spinal metastases in pediatric H3K27M-mutant pineal parenchymal tumor of intermediate differentiation: case report. Journal Of Neurosurgery. Pediatrics 2019, 1-10. PMID: 31653819, DOI: 10.3171/2019.8.PEDS18664.
  • Low-Grade Astrocytoma within a Mature Cystic Teratoma in an Adolescent Patient.Yoder N, Marks A, Hui P, Litkouhi B, Cron J. Low-Grade Astrocytoma within a Mature Cystic Teratoma in an Adolescent Patient. Journal Of Pediatric And Adolescent Gynecology 2018, 31: 325-327. PMID: 29107097, DOI: 10.1016/j.jpag.2017.10.005.
  • SOX2 immunity and tissue resident memory in children and young adults with glioma.Vasquez JC, Huttner A, Zhang L, Marks A, Chan A, Baehring JM, Kahle KT, Dhodapkar KM. SOX2 immunity and tissue resident memory in children and young adults with glioma. Journal Of Neuro-oncology 2017, 134: 41-53. PMID: 28620836, PMCID: PMC7906294, DOI: 10.1007/s11060-017-2515-8.
  • Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children.Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB. Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. JAMA Oncology 2016, 2: 1574-1581. PMID: 27491009, DOI: 10.1001/jamaoncol.2016.2547.

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
PediatricsA Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Brain and Nervous System; PediatricsA Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Leukemia, not otherwise specified; Leukemia, other; PediatricsA Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Leukemia, other; PediatricsA Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Bones and Joints; Kidney; Soft Tissue; PediatricsPhase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
Other Hematopoietic; Pediatrics; Sickle Cell DisordersA Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
Bones and Joints; Brain and Nervous System; Eye and Orbit; Hodgkin's Lymphoma; Kidney; Leukemia, other; Liver; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Small Intestine; Soft Tissue; PediatricsThe Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Edit Profile